Advertisement

Advertisement
Immunotherapy
Lung Cancer

Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer

In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy...

Head and Neck Cancer

Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma

In a single-center phase II trial reported in the Journal of Clinical OncologyRenata Ferrarotto, MD, and colleagues found that the...

Gastroesophageal Cancer

Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer

A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction...


Advertisement
Lung Cancer

Detection of Emphysema During Lung Cancer Screening

In an article published in Annals of the American Thoracic SocietyJames L. Mulshine, MD, and colleagues maintained that the high frequency...

Hepatobiliary Cancer

What Can Be Learned From Negative Findings of Two Trials in Biliary Tract Cancer

Biliary tract cancer is particularly difficult to treat, with a median overall survival of about 1 year with standard-of-care gemcitabine-based...

Advertisement




Solid Tumors
Gastrointestinal Cancer
Genomics/Genetics

Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib

Breast Cancer
Integrative Oncology

Use of Integrative Medicine by Patients With Breast Cancer

Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that less than half (43%) of patients were using these approaches during cancer care. These and other findings from a...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: Comparing Cisplatin and Gemcitabine With or Without Berzosertib

Leukemia
Immunotherapy

Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL

The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...

Bladder Cancer
Immunotherapy

KEYNOTE-361: First-Line Pembrolizumab With or Without Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Carcinoma

As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Terry P. Mamounas, MD, MPH, on Breast Cancer: Extended Aromatase Inhibitor Therapy

Gastroesophageal Cancer
Immunotherapy

Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer

The first results from the phase III CheckMate 648 study represent significant progress in the treatment of patients with advanced esophageal squamous cell carcinoma. The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...